JPS6322517A - 皮膚病に対するアリ−ルオキシカルボン酸誘導体の用途 - Google Patents

皮膚病に対するアリ−ルオキシカルボン酸誘導体の用途

Info

Publication number: JPS6322517A
Authority: JP; Japan
Prior art keywords: item; drug according; acid derivative; diseases; treatment
Prior art date: 1986-06-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP62165137A

Other languages

English (en)

Japanese (ja)

Inventor

ラツロ・イルク

マリオ・グリゴラ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-30

Filing date

1987-06-30

Publication date

1988-01-30

1987-06-30 Application filed by Individual filed Critical Individual

1988-01-30 Publication of JPS6322517A publication Critical patent/JPS6322517A/ja

Status Pending legal-status Critical Current

Links

239000002253 acid Substances 0.000 title claims description 16
208000017520 skin disease Diseases 0.000 title description 5
239000003814 drug Substances 0.000 claims description 24
229940079593 drug Drugs 0.000 claims description 19
239000000499 gel Substances 0.000 claims description 19
239000000243 solution Substances 0.000 claims description 18
239000002674 ointment Substances 0.000 claims description 13
201000004384 Alopecia Diseases 0.000 claims description 12
102000008186 Collagen Human genes 0.000 claims description 11
108010035532 Collagen Proteins 0.000 claims description 11
229920001436 collagen Polymers 0.000 claims description 11
229960001214 clofibrate Drugs 0.000 claims description 10
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 10
230000003676 hair loss Effects 0.000 claims description 8
239000000725 suspension Substances 0.000 claims description 8
208000011580 syndromic disease Diseases 0.000 claims description 8
206010003694 Atrophy Diseases 0.000 claims description 6
206010007882 Cellulitis Diseases 0.000 claims description 6
231100000360 alopecia Toxicity 0.000 claims description 6
230000037444 atrophy Effects 0.000 claims description 6
206010012601 diabetes mellitus Diseases 0.000 claims description 6
230000017074 necrotic cell death Effects 0.000 claims description 6
206010033675 panniculitis Diseases 0.000 claims description 6
208000030507 AIDS Diseases 0.000 claims description 5
208000032544 Cicatrix Diseases 0.000 claims description 5
206010015150 Erythema Diseases 0.000 claims description 5
206010016936 Folliculitis Diseases 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
231100000321 erythema Toxicity 0.000 claims description 5
231100000241 scar Toxicity 0.000 claims description 5
230000037387 scars Effects 0.000 claims description 5
208000027932 Collagen disease Diseases 0.000 claims description 4
229960002297 fenofibrate Drugs 0.000 claims description 4
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 4
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
229960004544 cortisone Drugs 0.000 claims description 3
XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
235000019155 vitamin A Nutrition 0.000 claims description 3
239000011719 vitamin A Substances 0.000 claims description 3
208000005230 Leg Ulcer Diseases 0.000 claims description 2
208000029578 Muscle disease Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
206010039710 Scleroderma Diseases 0.000 claims description 2
201000001981 dermatomyositis Diseases 0.000 claims description 2
229960003501 etofibrate Drugs 0.000 claims description 2
210000003734 kidney Anatomy 0.000 claims description 2
210000004185 liver Anatomy 0.000 claims description 2
210000004072 lung Anatomy 0.000 claims description 2
206010025135 lupus erythematosus Diseases 0.000 claims description 2
229940086198 Corticosteroid antagonist Drugs 0.000 claims 1
239000003836 corticosteroid antagonist Substances 0.000 claims 1
201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
208000019553 vascular disease Diseases 0.000 claims 1
238000011282 treatment Methods 0.000 description 32
208000025865 Ulcer Diseases 0.000 description 17
231100000397 ulcer Toxicity 0.000 description 16
206010040925 Skin striae Diseases 0.000 description 13
210000001789 adipocyte Anatomy 0.000 description 8
238000002604 ultrasonography Methods 0.000 description 8
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000004177 elastic tissue Anatomy 0.000 description 6
210000004209 hair Anatomy 0.000 description 6
210000003491 skin Anatomy 0.000 description 6
229940088594 vitamin Drugs 0.000 description 6
229930003231 vitamin Natural products 0.000 description 6
235000013343 vitamin Nutrition 0.000 description 6
239000011782 vitamin Substances 0.000 description 6
210000002615 epidermis Anatomy 0.000 description 5
208000004197 mesenchymoma Diseases 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
229960001334 corticosteroids Drugs 0.000 description 4
238000010562 histological examination Methods 0.000 description 4
230000003902 lesion Effects 0.000 description 4
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
206010024612 Lipoma Diseases 0.000 description 3
JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 3
206010040799 Skin atrophy Diseases 0.000 description 3
229930003427 Vitamin E Natural products 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
210000003141 lower extremity Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000019156 vitamin B Nutrition 0.000 description 3
239000011720 vitamin B Substances 0.000 description 3
235000019165 vitamin E Nutrition 0.000 description 3
229940046009 vitamin E Drugs 0.000 description 3
239000011709 vitamin E Substances 0.000 description 3
150000003722 vitamin derivatives Chemical class 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
-1 Clofibrinic acid ester Chemical class 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
206010063560 Excessive granulation tissue Diseases 0.000 description 2
XJGBDJOMWKAZJS-UHFFFAOYSA-N Nafenoic Acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C2=CC=CC=C2CCC1 XJGBDJOMWKAZJS-UHFFFAOYSA-N 0.000 description 2
206010039792 Seborrhoea Diseases 0.000 description 2
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
229930003270 Vitamin B Natural products 0.000 description 2
239000003524 antilipemic agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
229940125753 fibrate Drugs 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
210000001126 granulation tissue Anatomy 0.000 description 2
208000024963 hair loss Diseases 0.000 description 2
230000036074 healthy skin Effects 0.000 description 2
230000001969 hypertrophic effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
230000037390 scarring Effects 0.000 description 2
229960004058 simfibrate Drugs 0.000 description 2
210000004304 subcutaneous tissue Anatomy 0.000 description 2
235000019158 vitamin B6 Nutrition 0.000 description 2
239000011726 vitamin B6 Substances 0.000 description 2
229940045997 vitamin a Drugs 0.000 description 2
229940011671 vitamin b6 Drugs 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 description 1
208000029147 Collagen-vascular disease Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
235000009161 Espostoa lanata Nutrition 0.000 description 1
240000001624 Espostoa lanata Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010030201 Oesophageal ulcer Diseases 0.000 description 1
208000007117 Oral Ulcer Diseases 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
208000035977 Rare disease Diseases 0.000 description 1
108010081750 Reticulin Proteins 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
206010044546 Traumatic ulcer Diseases 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
230000001139 anti-pruritic effect Effects 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229950008441 clofibric acid Drugs 0.000 description 1
CXQGFLBVUNUQIA-UHFFFAOYSA-N clofibride Chemical compound CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 CXQGFLBVUNUQIA-UHFFFAOYSA-N 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
208000028299 esophageal disease Diseases 0.000 description 1
208000019064 esophageal ulcer Diseases 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
208000000069 hyperpigmentation Diseases 0.000 description 1
230000003810 hyperpigmentation Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000004132 lipogenesis Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
BXZXQTXKLQAOEF-UHFFFAOYSA-N n-(3-hydroxypropyl)butanamide Chemical compound CCCC(=O)NCCCO BXZXQTXKLQAOEF-UHFFFAOYSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
239000002667 nucleating agent Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940101267 panthenol Drugs 0.000 description 1
235000020957 pantothenol Nutrition 0.000 description 1
239000011619 pantothenol Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003774 positive effect on hair Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229960003471 retinol Drugs 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
210000002374 sebum Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
241000894007 species Species 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
WRCITXQNXAIKLR-UHFFFAOYSA-N tiadenol Chemical compound OCCSCCCCCCCCCCSCCO WRCITXQNXAIKLR-UHFFFAOYSA-N 0.000 description 1
229960000822 tiadenol Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000025366 tissue development Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

JP62165137A 1986-06-30 1987-06-30 皮膚病に対するアリ−ルオキシカルボン酸誘導体の用途 Pending JPS6322517A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3621861.8		1986-06-30
DE19863621861 DE3621861A1 (de)	1986-06-30	1986-06-30	Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen

Publications (1)

Publication Number	Publication Date
JPS6322517A true JPS6322517A (ja)	1988-01-30

Family

ID=6304027

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62165137A Pending JPS6322517A (ja)	1986-06-30	1987-06-30	皮膚病に対するアリ−ルオキシカルボン酸誘導体の用途

Country Status (4)

Country	Link
US (1)	US4871752A (de)
EP (1)	EP0254869A3 (de)
JP (1)	JPS6322517A (de)
DE (1)	DE3621861A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2044643A1 (de)	1970-08-07	1972-02-10	Bbc Brown Boveri & Cie	Druckgasschalter
JP2007070350A (ja) *	2005-08-10	2007-03-22	Rohto Pharmaceut Co Ltd	眼粘膜適用製剤
JP2008531550A (ja) *	2005-02-23	2008-08-14	ソグ−ニョンべ，	クエン酸、亜鉛およびアルギニンからなる皮膚線条予防および治療用組成物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5662934A (en) *	1993-01-05	1997-09-02	Najarian; Thomas	Compositions and methods for lowering cholesterol while maintaining antioxidant levels
DE4317127A1 (de) *	1993-05-19	1994-11-24	Merz & Co Gmbh & Co	Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie
US5755680A (en) *	1994-11-01	1998-05-26	Ghodsian; Kamran	Method for inhibiting the formation of striations due to skin tension
AU5928898A (en) *	1997-01-24	1998-08-18	Regents Of The University Of California, The	Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
USRE37770E1 (en)	1997-01-24	2002-06-25	The Regents Of The University Of California	Treatment of skin conditions by use of PPARα activators
US6071955A (en) *	1999-02-25	2000-06-06	The Regents Of The University Of California	FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1353695A2 (de) *	2001-01-26	2003-10-22	Schering Corporation	Kombinationen von einem hemmer der sterol-absorption und nicotinsäure zur behandlung von kardiovaskulären indikationen
RS20100015A (sr) *	2001-01-26	2010-12-31	Schering Corporation	Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US7071181B2 (en) *	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156585A0 (en) *	2001-01-26	2004-01-04	Schering Corp	Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
ATE369851T1 (de) *	2001-01-26	2007-09-15	Schering Corp	Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
IL156488A0 (en) *	2001-01-26	2004-01-04	Schering Corp	Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
PT1355644E (pt) *	2001-01-26	2006-11-30	Schering Corp	Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
DE60216275T2 (de) *	2001-05-25	2007-06-21	Schering Corp.	Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
CN101785772A (zh) *	2001-09-21	2010-07-28	先灵公司	使用甾醇吸收抑制剂治疗或预防脉管炎的方法
US7053080B2 (en) *	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) *	2001-09-21	2003-06-26	Schering Corporation	Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
EP1429756B1 (de) *	2001-09-21	2006-11-22	Schering Corporation	Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7056906B2 (en) *	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2006508188A (ja) *	2002-11-06	2006-03-09	シェーリング　コーポレイション	脱髄の処置のためのコレステロール吸収インヒビター
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de)	2003-03-07	2008-10-09	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756756A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
JP2007510659A (ja) *	2003-11-05	2007-04-26	シェーリング　コーポレイション	脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
RU2284178C1 (ru) *	2005-03-10	2006-09-27	Военно-медицинский институт Федеральной службы безопасности Российской Федерации (ВМИ ФСБ России)	Способ лечения липоидного некробиоза у детей

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB860303A (en) *	1958-06-20	1961-02-01	Ici Ltd	Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3769431A (en) *	1969-06-18	1973-10-30	American Home Prod	Method of reducing serum cholesterol with 2-phenoxyalkanoic acid esters
GB1487544A (en) *	1975-05-11	1977-10-05	Dso Pharmachim	Dermatological composition
US4310512A (en) *	1977-08-29	1982-01-12	Bush Boake Allen Inc.	Derivatives of acetic and propionic acids, compositions containing same and use as malodor counteractants

1986
- 1986-06-30 DE DE19863621861 patent/DE3621861A1/de not_active Withdrawn
1987
- 1987-06-24 EP EP87109036A patent/EP0254869A3/de not_active Withdrawn
- 1987-06-30 US US07/068,100 patent/US4871752A/en not_active Expired - Fee Related
- 1987-06-30 JP JP62165137A patent/JPS6322517A/ja active Pending

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2044643A1 (de)	1970-08-07	1972-02-10	Bbc Brown Boveri & Cie	Druckgasschalter
JP2008531550A (ja) *	2005-02-23	2008-08-14	ソグ−ニョンべ，	クエン酸、亜鉛およびアルギニンからなる皮膚線条予防および治療用組成物
JP2007070350A (ja) *	2005-08-10	2007-03-22	Rohto Pharmaceut Co Ltd	眼粘膜適用製剤

Also Published As

Publication number	Publication date
DE3621861A1 (de)	1988-01-14
EP0254869A3 (de)	1990-05-09
EP0254869A2 (de)	1988-02-03
US4871752A (en)	1989-10-03

Publication	Publication Date	Title
US4871752A (en)	1989-10-03	Use of aryloxycarboxylic acid derivatives against dermatological diseases
US4839159A (en)	1989-06-13	Topical L-carnitine composition
US5122536A (en)	1992-06-16	Method for the topical treatment of psoriasis
DE69529345T2 (de)	2003-10-30	Wundheilendes sonnenschutzmittel
DE3750836T2 (de)	1995-05-04	Zwei-stufen-verfahren zur heilung schmerzenfreier wunden, sowie wässriges medium und topische salbe zur verwendung dazu.
US4603146A (en)	1986-07-29	Methods for retarding the effects of aging of the skin
AU598454B2 (en)	1990-06-28	Compositions and methods for retarding the effects of aging of the skin
Bansal et al.	1993	Comparison of topical phenytoin with normal saline in the treatment of chronic trophic ulcers in leprosy
JPH08500092A (ja)	1996-01-09	皮膚科用組成物
Hazen et al.	1982	Cutaneous calcinosis of scleroderma: successful treatment with intralesional adrenal steroids
AU754420B2 (en)	2002-11-14	Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
FRY et al.	1970	Effect of Eetinoic acid in psoriasis
JP2000511168A (ja)	2000-08-29	局所的適用のための製品としてのビタミンｅのエステル
JPH04500824A (ja)	1992-02-13	光老化の作用を回復させるための皮膚の治療方法
EP1906984A2 (de)	2008-04-09	Arbutin, ascorbinsäure, oleuropeina oder derivate davon umfassender molekülkomplex und damit verbundene verwendungen auf dem gebiet der medizin
US4189487A (en)	1980-02-19	Use of pyridine aldehydes for the prevention and treatment of acne vulgaris
AU754680B2 (en)	2002-11-21	Use of 17-alpha-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy
RU2128500C1 (ru)	1999-04-10	Мазь б.и.варфоломеева для лечения ожогов
DE3781662T2 (de)	1993-03-25	Wundheilende arzneimittel und kosmetika.
US6488940B2 (en)	2002-12-03	Use of 17-α-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy
JPH072621A (ja)	1995-01-06	化粧料
RU2152205C1 (ru)	2000-07-10	Лекарственный препарат для лечения проктологических заболеваний
JP3491907B2 (ja)	2004-02-03	肥厚性瘢痕、ケロイド用皮膚外用剤
DE2840173C2 (de)	1980-09-04	Mittel zur Wiederherstellung der Zellfunktionen bei Gewebedefekten infektiöser oder degenerativer Art, verzögerter Wundheilung, altersbedingten Symptomen und depressiven Gemütszuständen
KR20010025824A (ko)	2001-04-06	여드름 피부용 화장료 조성물

JPS6322517A - 皮膚病に対するアリ−ルオキシカルボン酸誘導体の用途 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=6304027

Family Applications (1)

Country Status (4)

Cited By (3)

Families Citing this family (27)

Family Cites Families (4)

Cited By (3)

Also Published As

Similar Documents